Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11682
Title: Sugammadex.
Austin Authors: Karalapillai, Dharshi ;Kaufman, Melissa;Weinberg, Laurence 
Affiliation: Austin Health, Heidelberg, Victoria, Australia, Australia
Issue Date: 1-Mar-2013
Publication information: Critical Care and Resuscitation; 15(1): 57-62
Abstract: Sugammadex is the first selective antagonist to reverse neuromuscular blockade induced by rocuronium and vecuronium. The mechanism by which sugammadex works is superior to current neuromuscular block reversal strategies in terms of speed, efficacy and side effects. There is little contemporary guidance on the use of sugammadex in intensive care medicine. This review covers the key pharmacological features, clinical uses and cost- effectiveness in the context of intensive care practice.
Gov't Doc #: 23432503
URI: http://ahro.austin.org.au/austinjspui/handle/1/11682
URL: https://pubmed.ncbi.nlm.nih.gov/23432503
Type: Journal Article
Subjects: Humans
gamma-Cyclodextrins.pharmacology.therapeutic use
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on Dec 7, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.